Taflotan Adverse Reactions

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

The information highlighted (if any) are the most recent updates for this brand.

Full Prescribing Info

Adverse Reactions

Adverse drug reactions (including abnormal change in laboratory test values) were reported in 326 of 483 patients (67.5%). The major adverse reactions were conjunctival hyperaemia in 151 patients (31.3%), abnormality in eyelashes in 93 patients (19.3%), itching in 85 patients (17.6%), eye irritation in 65 patients (13.5%), and iris pigmentation in 39 patients (8.1%), etc.
Clinically significant adverse reaction: Iris pigmentation (8.1%): Since iris pigmentation may occur, patients should be examined periodically, and administration should be discontinued depending on the clinical status when iris pigmentation is observed.
Other adverse reactions: If an adverse drug reaction is observed, appropriate measures such as discontinuing administration should be taken. (See Table 3.)

Click on icon to see table/diagram/image

View ADR Monitoring Form

Taflotan Adverse Reactions

tafluprost

Manufacturer:

Santen

Marketer:

Meiji